Navigation Links
Affymetrix and bioMerieux Extend Their Agreement on GeneChip(R) Technology to Breast Cancer Diagnostics

Affymetrix Inc. (Nasdaq: AFFX) and bioMerieux announced today that Affymetrix has granted bioMerieux long-term and comprehensive access to its GeneChip(R) technology to develop and market in vitro diagnostic tests for breast cancer, as well as an option to expand the agreement into other cancer areas.

The agreement, made under the Powered by Affymetrix(TM) program, gives bioMerieux non-exclusive rights to Affymetrix' patented arrays, instrumentation systems and future improvements to these key technologies. Financial terms of the agreement were not disclosed.

"Microarrays are on the path to becoming a clinical reality in oncology, helping clinicians to provide a more holistic understanding of disease and treatment," said Dr. Dirk Lammerts, M.D., Affymetrix' Vice President of Molecular Diagnostics. "bioMerieux is at the cutting edge of diagnostic technology and we are pleased that they have chosen the Affymetrix platform for this project."

Under the Powered by Affymetrix(TM) program, Affymetrix provides technology and expertise for products that are developed, branded and marketed by diagnostic companies. This includes the GeneChip System 3000Dx, which has been granted regulatory clearance by the U.S. Food and Drug Administration and CE marked in the European Union for in-vitro diagnostic use.

"bioMerieux provides a full range of solutions for molecular diagnostics, from single to multiple and complex genetic targets, requiring the use of microarrays. Our extended agreement with Affymetrix broadens our rights beyond infectious diseases, food and water testing. The potential for microarrays in cancer application will be vast, ranging from diagnosis to personalized treatment," explained Dr Christophe Merieux, Vice President Research and Development - Medical Affairs.


'"/>

Source:Affymetrix


Page: 1

Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
3. Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance
4. Affymetrix and Stratagene Announce Strategic Software Alliance
5. Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences
6. Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX
7. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
8. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
9. Affymetrix 500K array used to identify memory gene
10. HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find
11. Scientists Propose Sweeping Changes to Naming of Bird Neurosystems to Acknowledge Their True Brainpower
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/30/2019)... ... December 30, 2019 , ... ... Association:, ,     Alzheimer's disease is the 6th leading cause of ... unpaid care for people with Alzheimer's or other dementia. ,     These caregivers ...
(Date:12/18/2019)... Mass. (PRWEB) , ... December 17, 2019 , ... ... R. Murrow Center for a Digital World at The Fletcher School, Tufts University, ... that will enhance the digital learning experience of students using Macmillan Learning’s acclaimed ...
(Date:12/14/2019)... ... December 12, 2019 , ... Crop Enhancement ... has appointed Jean Pougnier as chief business officer. Mr. Pougnier will lead the ... influencers that will position the company for maximum commercial success. As part of ...
Breaking Biology News(10 mins):
(Date:1/24/2020)... ... January 24, 2020 , ... ... by companies in biotechnology, diagnostics, therapeutics, laboratory and clinical services during the first ... people around the world. And as Slone Partners celebrates its 20th ...
(Date:1/23/2020)... ... January 22, 2020 , ... ... in the cosmetic surgery industry at two recent North American investor forums specializing ... the Canaccord Genuity Medical Technologies & Diagnostics Forum on November 21, 2019 in ...
(Date:1/22/2020)... ... 2020 , ... Microbial Discovery Group LLC (MDG) is pleased ... Institutional (I&I) Account Manager. Darrell will focus on servicing MDG’s partners with strategic ... years of sales experience working across multiple different market sectors such as; transportation, ...
(Date:1/22/2020)... FARMINGTON, Conn. (PRWEB) , ... January 21, 2020 , ... ... Cell (CTC) liquid biopsy from a simple blood draw, today announced the sale of ... UConn Health. The Rare Scope will be used in clinical cancer research. , “The ...
Breaking Biology Technology: